COMPANY PROFILE

Skylark Bio

Explore full profile

Pioneering gene therapies for patients with hearing loss

Cambridge, United StatesFounded 2021Biotech & Life Sciences

Valuation $100–250M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Skylark Bio

Skylark Bio is a biotechnology company focused on developing innovative gene therapies to address sensory limitations, particularly in the field of hearing. The company operates in the healthcare and biotech market, targeting patients with sensory impairments. Skylark Bio's business model revolves around the research, development, and commercialization of gene therapy solutions. The company generates revenue through the sale of its proprietary gene therapy products and potential licensing agreements. Skylark Bio leverages its expertise in virus vector bioengineering, particularly with adeno-associated virus (AAV) vectors, to create effective treatments. The company collaborates with leading scientists and institutions to advance its research and bring cutting-edge therapies to market.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: Cambridge, United States
Employees: 19
Open positions: 1
Dealroom signal: 53.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Apr 2024	$40M	$160M	ARCH Venture Partners · B-FLEXION	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Skylark Bio website traffic

Latest recorded traffic for Skylark Bio is 120 monthly website visits, down 91.4% over the last three months. Skylark Bio's team grew 26.7% over the past year.

Latest monthly visits120 3-month web change-91.4% 1-year team growth+26.7%

Monthly website visitsApr 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Director, CMC Development, Technical OperationsCambridge, MA · Project Management · Jul 2, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
RTR1 TherapeuticsPharmaceutical therapies targeting neurological, metabolic and infectious conditions	Temecula, United States	Operational	16	$78M	$310M
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
SISPES Pharmaceuticals Inc.The company focuses on the research and development of improved specialty injectable products 505(b)(2)and complex generic drugs	United States	Operational
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
MTMestag TherapeuticsDeveloping antibody therapeutics targeting fibroblast-immune interactions	Little Chesterford, United Kingdom	Operational
EHEdifice HealthOffers inflammatory health monitoring tests to help manage chronic inflammation and improve overall health and longevity	San Mateo, United States	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational